Consequently of the deleterous resistance and enhanced aggressivity brought to cancer cells by HspB1, a high level of expression of this molecular chaperone usually results in poor clinical outcome in the case of gastric, uterine, breast, prostate, ovarian, kidney and head/neck cancers as well as in tumors from the urinary and nervous systems [2,20,21,26,27]. This evidence concerns the gene HSPB1 and cancer.